Centric Wealth Management Raises Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Centric Wealth Management increased its stake in Gilead Sciences by 34.0%, owning 21,287 shares valued at approximately $2,385,000 as of the latest filing.
• After recent upgrades from various analysts, Gilead Sciences has a consensus rating of "Moderate Buy" with an average price target of $115.39.
• The company reported a quarterly earnings of $2.01 EPS, surpassing analyst expectations, and plans to distribute a quarterly dividend of $0.79 on September 29th.

Centric Wealth Management boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 34.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,287 shares of the biopharmaceutical company's stock after buying an additional 5,396 shares during the quarter. Centric Wealth Management's holdings in Gilead Sciences were worth $2,385,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the first quarter worth $25,000. Activest Wealth Management grew its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the first quarter worth $29,000. Colonial Trust Advisors grew its holdings in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital grew its holdings in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on GILD shares. UBS Group lifted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $115.39.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock worth $9,371,330. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $112.97 on Friday. Gilead Sciences, Inc. has a one year low of $77.74 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market cap of $140.17 billion, a price-to-earnings ratio of 22.50, a PEG ratio of 0.70 and a beta of 0.33. The firm's fifty day moving average is $113.01 and its two-hundred day moving average is $109.59.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the company earned $2.01 earnings per share. The firm's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.